TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05281068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Oral danazol (200 mg twice daily) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Oral danazol (200 mg twice daily) for 12 weeks.
Study: NCT05373316

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated MR-guided radiotherapy boost
Description: External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MRI.
Study: NCT06120933

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hair Nutra Growth Supplement & Hair Nutra Boost Supplement
Description: Study Initiation (Week 0) to Week 8:~Each participant will take both the Hair Nutra Growth capsules and the Hair Nutra Boost capsules.~Participants should take 2 capsules of Hair Nutra Growth daily, one in the morning and one in the afternoon, with food or after a meal. The capsules should be taken with water.~Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hair Nutra Growth
Description: From Week 9 to Week 12:~Participants should ONLY take the Hair Nutra Growth. Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water.
Study: NCT04487938

Intervention type: OTHER
Intervention: No intervention utilised
Description: No intervention utilised

Intervention type: OTHER
Intervention: No intervention utilised
Description: No intervention utilised
Study: NCT06788938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab treatment
Description: * 1 mg step dose on cycle 1 day 1 (C1D1)~* 10 mg target dose on cycle 1 day 8 (C1D8), and cycle 1 day 15 (C1D15) in a 28-day cycle.~* 10 mg Q2W subsequently (i.e., C2 + D1/D15 dosing) in a 28-day cycle
Study: NCT06791538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Gastrectomy
Description: The intervention measures for robotic gastrectomy include:~Preoperative Preparation: Comprehensive preoperative examinations, including imaging studies, laboratory tests, and tumor marker assessments, to confirm the diagnosis and staging.~Surgical Procedure: Utilizing the da Vinci Surgical System, which provides a high-definition 3D view and flexible robotic arms for enhanced surgical precision.~Lymphadenectomy: Systematic D2 lymph node dissection according to oncological standards to ensure thorough removal of regional lymph nodes.~Gastrectomy and Reconstruction: Performing subtotal or total gastrectomy based on tumor location and extent, with intracorporeal reconstruction assisted by the robotic system.~Postoperative Management: Close monitoring of vital signs, pain management, and early mobilization to facilitate recovery, along with prevention and management of postoperative complications.
Study: NCT05869266

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: professional fitting vs. self fitting
Description: Licensed professional fits the hearing aid fitting using professional programing tools and thresholds obtained from the traditional audiometry vs. subject performs self-fitting of the hearing aids using the Tuned App.
Study: NCT06791538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Gastrectomy
Description: Preoperative Preparation: Confirm diagnosis and staging through imaging and laboratory tests.~Surgical Procedure: Use standard laparoscopic instruments and 2D HD camera. Lymphadenectomy: Perform systematic D2 lymph node dissection. Gastrectomy and Reconstruction: Conduct subtotal or total gastrectomy and intracorporeal reconstruction.~Postoperative Management: Monitor vital signs, manage pain, and promote early mobilization.
Study: NCT05445336

Intervention type: BEHAVIORAL
Intervention: PREVENT Program
Description: PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.

Intervention type: BEHAVIORAL
Intervention: PREVENT Program
Description: PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.

Intervention type: BEHAVIORAL
Intervention: PREVENT Program
Description: PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.
Study: NCT05808023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP powder reintroduction
Description: The FODMAP powders will be reintroduced in three different doses, each for three consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP powder reintroduction
Description: The FODMAP powders will be reintroduced in three different doses, each for three consecutive days.
Study: NCT05333640

Intervention type: DEVICE
Intervention: Sirolimus Drug Coated Balloon
Description: AVFs treated with SDCB

Intervention type: DEVICE
Intervention: Paclitaxel Drug Coated Balloon
Description: AVFs treated with PDCB
Study: NCT04731922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-510
Description: TAK-510 solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-510
Description: TAK-510 solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-510
Description: TAK-510 solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-510 Placebo
Description: TAK-510 placebo-matching solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-510 Placebo
Description: TAK-510 placebo-matching solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-510 Placebo
Description: TAK-510 placebo-matching solution.
Study: NCT04904562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II
Description: Angiotensin II started at 5 ng/kg/min and titrated in 5-10 ng/kg/min increments every 5 minutes up to 80ng/kg/min to achieve target arterial pressure (MAP)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06792474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine in Saline
Description: Lidocaine infusion 1.5 mg/kg/hr

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion
Study: NCT06298383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trypsin, Bromelain and Rutoside
Description: Flamogen is a combination of trypsin 48 mgs, bromelain 90mg and rutoside 100 mg in one tablet that provides an anti inflammatory, anti edematous activity. each patient will receive a single dose of 2 tablets one hour before treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Potassium
Description: Non-steroidal anti inflammatory drug. cataflam is known for its potent anti inflammatory and analgesic properties. each patient will receive one tablet of cataflam 50 mg 1 hour before treatment.
Study: NCT05878691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 54276
Description: Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm.
Study: NCT06298383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Oral Tablet
Description: Steroids are potent anti inflammatory drugs, patients are going to receive one tablet of 30 mg solupred one hour before treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A tablet of Compacted powdered milk
Study: NCT05878691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 54276 + Pembrolizumab
Description: Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days.~Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 54276 + Atezolizumab
Description: Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days.~Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm.
Study: NCT04587960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed primary closure of skin incision in Caesarean section in experimental group
Description: Delayed closure of skin wound of emergency Caesarean section following wound dressing for 2-3 days in experimental group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary closure of skin incision in Caesarean section in active comparator group
Description: Primary closure of skin wound (incisional) at the time of emergency Caesarean section in active comparator group
Study: NCT04919772

Intervention type: OTHER
Intervention: Assessment
Description: The participants walk 4-meter and 10-meter and 5-repetition sit-to-stand twice.
Study: NCT06013319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: The load dose of esmolol was first injected intravenously: 0.5mg/kg.min, for about 1 minute; then the maintenance dose was pumped intravenously: from 0.05mg/kg/min, and continued after 4 minutes if the efficacy was ideal; if the efficacy was poor, the load dose could be repeated and the maintenance dose increased by 0.05mg/kg/min. The maintenance dose should not exceed 0.3mg/kg/min.
Study: NCT04853277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Each Patient will undergo a 30 minute telephone visit with a trained Medical Provider outlining the timeline of various common emotional challenges experienced after transplant/CAR-T, as well as coping techniques. A pamphlet with information discussed will also be provided to the patient to review on their own time. The patient will have an opportunity to express any psychosocial/emotional concerns at this time.
Study: NCT05265962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine plus Penpulimab
Description: Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
Study: NCT05227768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 25mg Group
Description: 4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 25mg Group
Description: 4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 200mg Group
Description: 6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 200mg Group
Description: 6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 400mg Group
Description: 6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 400mg Group
Description: 6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 800mg Group
Description: 6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 800mg Group
Description: 6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 1200mg Group
Description: 6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 1200mg Group
Description: 6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.
Study: NCT05386849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FUSION closed loop glucose control system
Description: The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
Study: NCT05166551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: This study will be conducted in a randomized placebo-controlled research design to investigate the effect of acupressure, to be applied to the Gall Bladder (GB) 31 Fengshi acupuncture point before the vaccinations, on interventional pain in infants (0-1 years) caused by the vaccine.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupressure
Description: Placebo Acupressure
Study: NCT04770181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Stim AID CES (Active Comparator)
Description: The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Alpha-Stim AID CES (Sham Comparator)
Description: The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
Study: NCT06790420

Intervention type: DRUG
Intervention: Rituximab Pfizer
Description: For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times

Intervention type: DRUG
Intervention: Rituxan
Description: For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times
Study: NCT06791902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive DBS
Description: Adapting DBS stimulation based on locomotor states
Study: NCT05053100

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT06785467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eDoula App
Description: eDoula is an app that will give patients reading material and videos to watch based on their due date. It also provides helpful postpartum device.
Study: NCT06792292

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional colonoscopy procedure
Description: Study subjects in this interventional arm will undergo conventional colonoscopy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: artificial intelligence-assisted colonoscopy procedure
Description: Study subjects in this interventional arm will undergo colonoscopy done with a commercially-available module that uses artificial intelligence to highlight suspected polyps on the screen during colonoscopy. This module also attempts to characterize the detected polyp as adenomatous or not. The detection and characterization of polyps is in real time, during the procedure.
Study: NCT06790576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closed-loop-peak
Description: With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: closed-loop-peak (each pulse synchronized to person's peak of theta waveform)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open-loop
Description: With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: open-loop (TMS pulse delivered without regard to EEG)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closed-loop-trough
Description: With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: closed-loop-trough (each pulse synchronized to trough of theta waveform)
Study: NCT06792227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT-H
Description: FBT is a structured treatment lasting 6-12 months, typically in an outpatient setting, with weekly sessions that gradually decrease in frequency over time (Lock \& Le Grange, 2015). It empowers parents to manage their child's recovery from the ED. The first phase focuses on weight restoration, with parents responsible for all eating decisions and restricting physical activity to reduce ED's influence. In the second phase, eating responsibility gradually shifts back to the adolescent. The final phase supports healthy adolescent development as ED symptoms subside.~The FBT-H adapts FBT to a home setting, with treatment led by family counselors and psychologists as part of a multidisciplinary team, including therapists, psychologists, a psychiatrist and a nurse specialist.
Study: NCT06790966

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Treatment of PDS0101 and Pembrolizumab
Description: * Pembrolizumab (IV) every 3 weeks for up to 35 Cycles~* PDS0101 (SC) during Cycles 1, 2, 3, 4, and 12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab Monotherapy
Description: Pembrolizumab (IV) every 3 weeks for up to 35 cycles.
Study: NCT06792526

Intervention type: OTHER
Intervention: IVIM Imaging MRF Imaging
Description: IVIM imaging will be performed to evaluate microstructural and perfusion changes in the salivary glands of Head and Neck Cancer undergoing radiotherapy. This technique quantifies diffusion and perfusion parameters, providing insights into early tissue damage. MRF imaging will be used to quantify salivary gland tissue characteristics, including relaxation parameters (T1 and T2 mapping), to monitor radiotherapy-induced damage. The technique enables precise tissue characterization through multi-parametric MRI.
Study: NCT06791239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic squeeze technique
Description: The Thoracic Squeeze Technique is a manual therapy method used primarily in respiratory physiotherapy to improve lung expansion, enhance respiratory function, and facilitate secretion clearance in patients with respiratory conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual diaphragmatic release technique
Description: The Manual Diaphragmatic Release Technique is a soft tissue manipulation technique used to improve the mobility, function, and efficiency of the diaphragm. It is commonly applied in physiotherapy, particularly in respiratory, musculoskeletal, and manual therapy practices, to address breathing dysfunctions, postural imbalances, and associated pain or discomfort.
Study: NCT06790849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active 1 ETAS®
Description: 300 mg ETAS®

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active 2 ETAS®
Description: 1500mg ETAS®

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsule
Study: NCT06792084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: Motivational interviewing is a directive and client-centered approach used to elicit behavioral change by helping the client explore and resolve ambivalence. Motivational interviewing is a specific method of helping individuals understand their problems and take action for change. In this study, the motivational interview program created in line with the literature (Li et al, 2023; Miller and Rollnick, 2013; Çelik Örücü, 2020) consists of 5 sessions in total, one session per week. There are specific goals and objectives for each session.
Study: NCT06791187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: BI 1291583
Study: NCT06790654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-message based motivational interviewing
Description: Participants will receive weekly text messages during the pilot study period, initiated and managed by MItrained interviewers. Each text message exchange will begin with a short, MI-consistent prompt developed with input from focus groups of mothers who have previously breastfed. These prompts will address common breastfeeding barriers. Following the initial prompt, MI-trained trainers will engage with participants through text exchanges that utilize the core MI OARS skills (open-ended questions, affirmations, reflections, or summaries) to facilitate change talk.
Study: NCT06792487

Intervention type: PROCEDURE
Intervention: skin biopsy
Description: punch biopsy (6 mm) of lesional psoriasis skin

Intervention type: PROCEDURE
Intervention: skin biopsy
Description: punch biopsy (6 mm) of lesional psoriasis skin
Study: NCT05053100

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Undergo electronic health record review
Study: NCT05026255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar recruitment manoeuvre by pressure step
Description: The application of alveolar recruitment manoeuvres consists of transiently increasing alveolar pressure in order to re-open collapsed alveolar territories and to re-ventilate poorly ventilated or non-ventilated lung areas.